Theravance Biopharma doses nOH patients in Phase 3 testing investigational inhibitor ampreloxetine

Theravance Biopharma has started dosing patients with symptomatic neurogenic orthostatic hypotension (nOH) to test its investigational neropinephrine reuptake inhibitor ampreloxetine (TD-9855), in a registrational Phase 3 clinical trial

Read more

Canopy Growth Corporation, Beckley Canopy Therapeutics join as exclusive distributors of newly formed Spectrum UK’s cannabis medicinal products in UK

The UK market focused joint venture between Canopy Growth Corporation and Beckley Canopy Therapeutics will exclusively distribute Cannabis medicinal products of newly formed, built-for-purpose distribution company that will introduce Spectrum Cannabis medicinal cannabis products to UK patients and doctors. 

Read more